Devices and technology: Continuous glucose monitoring

A prespecified analysis of the CONCEPTT trial shows that pregnant women with type 1 diabetes who were using pumps at baseline did not achieve as good glycemic control as those using multiple daily injections.

The Tandem Basal-IQ predictive low-glucose suspend insulin delivery system significantly reduces the proportion of time adults and children spend in hypoglycemia during 24-hour usage, show findings from the randomized crossover PROLOG trial.

Researchers have reported good accuracy, durability, and acceptability of the Eversense continuous glucose monitoring system in a group of primarily pediatric patients.

Prepubertal children with type 1 diabetes have greater glycemic variability than those who are pubertal or postpubertal, researchers have reported at the ADA’s 78th Scientific Sessions.

Just 1 week of continuous glucose monitoring can uncover hidden problems and lead to treatment changes and improved glucose control in patients with type 1 diabetes, say the DIACCOR study investigators.

Analysis of the DIAMOND study shows that continuous glucose monitoring in patients with type 1 diabetes could be considered cost-effective, although this depends on the value for money threshold used.

The HypoDE investigators have reported that use of continuous glucose monitoring results in large reductions in hypoglycemia among high-risk patients managing their type 1 diabetes with multiple daily injections.

Further findings from the pilot I-HART randomized trial suggest that switching from flash to continuous glucose monitoring reduces the time patients with type 1 diabetes spend in hypoglycemia

Flash glucose monitoring confers similar benefits for diabetes patients in the real world as for those using it in clinical trials, research shows.

Research shows that intervening to improve the diet quality of adolescents with type 1 diabetes does not exacerbate disordered eating behavior.

Research shows that continuous glucose monitoring reduces hypoglycemia risk and improves patient-reported outcomes among people with type 1 diabetes in real-world practice.

A pilot randomized study suggests that continuous glucose monitoring may be better than flash monitoring for reducing hypoglycemia in type 1 diabetes patients with impaired awareness.

The two diabetes-related Cochrane reviews published in October focused on diabetes during pregnancy; the first covered different methods of glucose monitoring, while the second compared oral antidiabetic agents with insulin, with both concluding that better quality research is needed to draw firm conclusions.

The CONCEPTT trial results suggest that the use of continuous glucose monitoring by pregnant women with type 1 diabetes improves glycemic control and neonatal outcomes relative to standard glucose monitoring.

Continuous glucose monitoring results in modest but significant improvements in glycemic control in patients with type 2 diabetes using basal–bolus insulin, show further results from the DIAMOND trial.

A analysis from the DIAMOND trial suggests that adding an insulin pump to continuous glucose monitoring leads to better glycemic control, but at the price of more hypoglycemia.

Read the linked commentary from Leonard Bertheau.

Glycated hemoglobin levels are higher for a given blood glucose level in Black patients with diabetes than they are in White people, shows a continuous glucose monitoring study.

Read the linked commentary from Jay Shubrook.

Continuous glucose monitoring is associated with improvements in diabetes-specific quality of life compared with self-monitoring among patients with type 1 diabetes who use multiple daily insulin injections, study results suggest.

Research suggests that a predictive low-glucose management system significantly reduces hypoglycemic events in children and adolescents with type 1 diabetes.

Results of a randomized trial suggest that continuous glucose monitoring can be used without regular confirmatory blood glucose monitoring among adult insulin pump users with well-controlled type 1 diabetes.